On 2026-02-15 08:01:06 (Saudi Time), Dr. Sulaiman Al Habib Medical Services Group announced its Annual financial results for the twelve months ended on December 31, 2025.

Element List	Explanation
The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year	Revenues for FY 2025 grew by 22.38% reaching SAR 13,706.90 million, compared to SAR 11,200.43 million in FY 2024, representing an increase of SAR 2,506.47 million. This growth was primarily driven by both the hospitals and pharmacies segments, supported by higher patient volumes and higher occupancy rates. As part of its ongoing growth strategy, the Group launched several new hospitals across key regions. In 2024, operations commenced at Al-Fayhaa Hospital (Al-Fayhaa District, Jeddah), Shamal Al Riyadh Hospital (Al-Sahafa District, Riyadh), and the Women’s Health Hospital (Rahmaniyah District, Riyadh). The expansion continued in 2025 with the commencement of operations at Al-Hamra Hospital (Al-Hamra District, Riyadh), Al-Kharj Hospital (Al-Jawhara District, Al-Kharj), and Al Muhammadiyah Hospital (Al Muhammadiyah District, Jeddah). Newly commissioned hospitals are currently in the ramp-up phase, and revenue contribution is expected to increase progressively as they move toward optimal utilization.
The reason of the increase (decrease) in the net profit during the current year compared to the last year is	EBITDA increased by 17.86% reaching SAR 3,506.95 million (FY 2024: SAR 2,975.43 million). EBITDA margin reached 25.59%. Net profit increased by 3.72% reaching SAR 2,401.47 million (FY 2024: SAR 2,315.29 million). This increase was primarily driven by higher revenues, partially offset by fixed operating costs associated with the newly launched hospitals that are still in their ramp-up stages and are expected to progressively reach optimal operational capacity.
Statement of the type of external auditor's report	Unmodified opinion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion)	na
Reclassification of Comparison Items	na
Additional Information	na
Attached Documents

Year-on-Year Performance Drivers

Sales increased 22.38% YoY to SAR 13,706.90 million, driven by higher patient volumes, increased occupancy rates, and the launch of six new hospitals across key regions in 2024 and 2025. Net profit grew modestly by 3.72% to SAR 2,401.47 million, as the strong revenue growth was partially offset by fixed operating costs associated with newly launched hospitals that are still in their ramp-up phases and have not yet reached optimal operational capacity.

Other Items

The external auditor issued an unmodified opinion with no additional comments, disclaimers, or adverse remarks noted. No material risks or concerns regarding going concern, debt covenant breaches, or other significant uncertainties were disclosed. The company shows no accumulated losses, maintaining positive shareholders' equity of SAR 7,901.72 million.

Original announcement:

Attached PDF document link:

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.